Use of an Ozone/oxygen Mixture As Primary Anticancer Therapy Through Intraperitoneal Insufflation

Squamous cell carcinomas of the ENT area (HNSCC) are a group of metastatic tumors with a high mortality rate in humans and animals. Since then discovered that the biomolecule ozone inhibits the growth of various cancer cells in vitro, we here applied the highly aggressive and lethal VX2 carcinoma HNSCC tumor model of New Zealand rabbits to test whether ozone exerts anti-tumor effects in vivo.Therapeutic insufflation of a medical Ozon-/Sauerstoff (O3/O2)-gas mixture in the peritoneum (O3/O2-Pneumoperitoneum) to an advanced stage of tumor disease led to a survival rate of 7 / 14 rabbits. Six of the seven surviving rabbits showed complete tumor regression and the absence of local or distant lung metastases.

Patents:
EP 2,222,288

Inventor(s): WERNER JOCHEN A [DE]; DUENNE ANJA-ALEXANDRA [DE]; MANDIC ROBERT [DE]; WEIHE EBERHARD [DE]; BETTE MICHAEL [DE]; SCHULZ SIEGFRIED

Type of Offer: Sale



« More Medical Patents

---